Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year High After Analyst Upgrade

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) reached a new 52-week high during trading on Tuesday after The Goldman Sachs Group raised their price target on the stock from $59.00 to $67.00. The Goldman Sachs Group currently has a buy rating on the stock. Enliven Therapeutics traded as high as $54.29 and last traded at $53.9850, with a volume of 303573 shares. The stock had previously closed at $51.67.

A number of other brokerages also recently commented on ELVN. Mizuho upped their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday. HC Wainwright increased their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, JonesTrading raised their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enliven Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $70.50.

Insider Activity at Enliven Therapeutics

In related news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the transaction, the director directly owned 41,884 shares of the company’s stock, valued at $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $2,233,800. This trade represents a 10.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,018 shares of company stock valued at $1,113,888 in the last ninety days. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently modified their holdings of ELVN. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after acquiring an additional 594 shares in the last quarter. Invesco Ltd. grew its holdings in Enliven Therapeutics by 4.3% in the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after purchasing an additional 913 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at $38,000. Finally, Swiss National Bank lifted its holdings in shares of Enliven Therapeutics by 1.7% during the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock valued at $990,000 after purchasing an additional 1,100 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Trading Up 4.5%

The stock has a market cap of $3.29 billion, a price-to-earnings ratio of -32.33 and a beta of 0.24. The stock has a 50-day moving average price of $44.64 and a two-hundred day moving average price of $36.36.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Research analysts predict that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.